JP5485172B2 - 新規な細胞増殖抑制性７−デアザプリンヌクレオシド - Google Patents

新規な細胞増殖抑制性７−デアザプリンヌクレオシド Download PDF

Info

Publication number
JP5485172B2
JP5485172B2 JP2010542509A JP2010542509A JP5485172B2 JP 5485172 B2 JP5485172 B2 JP 5485172B2 JP 2010542509 A JP2010542509 A JP 2010542509A JP 2010542509 A JP2010542509 A JP 2010542509A JP 5485172 B2 JP5485172 B2 JP 5485172B2
Authority
JP
Japan
Prior art keywords
compound
ddd
nmr
mhz
gem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010542509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509949A (ja
JP2011509949A5 (enExample
Inventor
マイケル ホセク，
ペトル ナウス，
Original Assignee
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー， アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー， アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック filed Critical インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー， アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック
Publication of JP2011509949A publication Critical patent/JP2011509949A/ja
Publication of JP2011509949A5 publication Critical patent/JP2011509949A5/ja
Application granted granted Critical
Publication of JP5485172B2 publication Critical patent/JP5485172B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/40—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data
    • H02J7/44—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data between battery management systems and power sources
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/485—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2010542509A 2008-01-18 2009-01-15 新規な細胞増殖抑制性７−デアザプリンヌクレオシド Active JP5485172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18
US61/022,247 2008-01-18
PCT/CZ2009/000004 WO2009089804A1 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013266910A Division JP2014058567A (ja) 2008-01-18 2013-12-25 新規な細胞増殖抑制性７−デアザプリンヌクレオシド

Publications (3)

Publication Number Publication Date
JP2011509949A JP2011509949A (ja) 2011-03-31
JP2011509949A5 JP2011509949A5 (enExample) 2013-02-21
JP5485172B2 true JP5485172B2 (ja) 2014-05-07

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010542509A Active JP5485172B2 (ja) 2008-01-18 2009-01-15 新規な細胞増殖抑制性７−デアザプリンヌクレオシド
JP2013266910A Withdrawn JP2014058567A (ja) 2008-01-18 2013-12-25 新規な細胞増殖抑制性７−デアザプリンヌクレオシド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013266910A Withdrawn JP2014058567A (ja) 2008-01-18 2013-12-25 新規な細胞増殖抑制性７−デアザプリンヌクレオシド

Country Status (18)

Country Link
US (1) US8093226B2 (enExample)
EP (2) EP3133080B1 (enExample)
JP (2) JP5485172B2 (enExample)
CN (1) CN101977923B (enExample)
AU (1) AU2009204568B2 (enExample)
CA (1) CA2711384C (enExample)
CY (2) CY1118104T1 (enExample)
DK (2) DK2231689T3 (enExample)
ES (2) ES2693551T3 (enExample)
HR (2) HRP20161344T1 (enExample)
HU (2) HUE041598T2 (enExample)
LT (2) LT3133080T (enExample)
NZ (1) NZ586610A (enExample)
PL (2) PL3133080T3 (enExample)
PT (2) PT3133080T (enExample)
SI (2) SI3133080T1 (enExample)
TR (1) TR201815961T4 (enExample)
WO (1) WO2009089804A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US9321800B2 (en) * 2009-04-22 2016-04-26 Gilead Sciences, Inc. 7-deazapurine nucleosides for therapeutic uses
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
NZ596479A (en) * 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
EP2640392B1 (en) * 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
KR102242077B1 (ko) 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
MX376856B (es) 2013-08-07 2025-03-07 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2018001393A1 (en) 2016-06-29 2018-01-04 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
KR20260080448A (ko) 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
US20220267365A1 (en) * 2019-06-18 2022-08-25 Taiho Pharmaceutical Co., Ltd. Novel phosphate ester compound having pyrrolopyrimidine skeleton or pharmaceutically acceptable salt thereof
EP4106763A1 (en) * 2020-02-17 2022-12-28 Katholieke Universiteit Leuven KU Leuven Research & Development Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (enExample) * 1974-03-19 1975-10-01
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
WO2005021568A2 (en) * 2003-08-27 2005-03-10 Biota, Inc. Novel tricyclic nucleosides or nucleotides as therapeutic agents
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
PL2231689T3 (pl) 2017-01-31
CA2711384A1 (en) 2009-07-23
AU2009204568B2 (en) 2013-10-03
PT2231689T (pt) 2016-10-07
DK2231689T3 (en) 2016-09-19
EP3133080B1 (en) 2018-08-01
AU2009204568A1 (en) 2009-07-23
HUE041598T2 (hu) 2019-05-28
NZ586610A (en) 2012-08-31
JP2011509949A (ja) 2011-03-31
US20090203637A1 (en) 2009-08-13
CN101977923B (zh) 2014-10-08
LT2231689T (lt) 2016-10-25
US8093226B2 (en) 2012-01-10
ES2598503T3 (es) 2017-01-27
JP2014058567A (ja) 2014-04-03
TR201815961T4 (tr) 2018-11-21
CN101977923A (zh) 2011-02-16
SI2231689T1 (sl) 2016-11-30
HUE030767T2 (en) 2017-05-29
PL3133080T3 (pl) 2018-12-31
LT3133080T (lt) 2018-11-12
CY1118104T1 (el) 2017-06-28
CY1121364T1 (el) 2020-05-29
CA2711384C (en) 2016-07-26
EP2231689A1 (en) 2010-09-29
HRP20161344T1 (hr) 2016-11-18
EP3133080A1 (en) 2017-02-22
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
EP2231689B1 (en) 2016-07-20
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
SI3133080T1 (sl) 2018-12-31
ES2693551T3 (es) 2018-12-12

Similar Documents

Publication Publication Date Title
EP3133080B1 (en) Novel cytostatic 7-deazapurine nucleosides
US10294262B2 (en) 7-deazapurine nucleosides for therapeutic uses
HK1234411B (en) Novel cytostatic 7-deazapurine nucleosides
HK1234411A1 (en) Novel cytostatic 7-deazapurine nucleosides
HK1149016B (en) Novel cytostatic 7-deazapurine nucleosides
US20110136754A1 (en) Novel triazole derivatives, their preparation and their application in therapeutics
HK1166325B (en) Novel 7-deazapurine nucleosides for therapeutic uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140219

R150 Certificate of patent or registration of utility model

Ref document number: 5485172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S633 Written request for registration of reclamation of name

Free format text: JAPANESE INTERMEDIATE CODE: R313633

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250